» Articles » PMID: 37231491

Tau Accumulation in Autosomal Dominant Alzheimer's Disease: a Longitudinal [F]flortaucipir Study

Abstract

Cortical tau accumulation is a key pathological event that partly defines Alzheimer's disease (AD) onset and is associated with cognitive decline and future disease progression. However, an improved understanding of the timing and pattern of early tau deposition in AD and how this may be tracked in vivo is needed. Data from 59 participants involved in two longitudinal cohort studies of autosomal dominant AD (ADAD) were used to investigate whether tau PET can detect and track presymptomatic change; seven participants were symptomatic, and 52 were asymptomatic but at a 50% risk of carrying a pathogenic mutation. All had baseline flortaucipir (FTP) PET, MRI and clinical assessments; 26 individuals had more than one FTP PET scan. Standardised uptake value ratios (SUVRs) in prespecified regions of interest (ROIs) were obtained using inferior cerebellar grey matter as the reference region. We compared the changes in FTP SUVRs between presymptomatic carriers, symptomatic carriers and non-carriers, adjusting for age, sex and study site. We also investigated the relationship between regional FTP SUVRs and estimated years to/from symptom onset (EYO). Compared to both non-carriers and presymptomatic carriers, FTP SUVRs were significantly higher in symptomatic carriers in all ROIs tested (p < 0.001). There were no significant regional differences between presymptomatic carriers and non-carriers in FTP SUVRs, or their rates of change (p > 0.05), although increased FTP signal uptake was seen posteriorly in some individuals around the time of expected symptom onset. When we examined the relationship of FTP SUVR with respect to EYO, the earliest significant regional difference between mutation carriers and non-carriers was detected within the precuneus prior to estimated symptom onset in some cases. This study supports preliminary studies suggesting that presymptomatic tau tracer uptake is rare in ADAD. In cases where early uptake was seen, there was often a predilection for posterior regions (the precuneus and post-cingulate) as opposed to the medial temporal lobe, highlighting the importance of examining in vivo tau uptake beyond the confines of traditional Braak staging.

Citing Articles

Investigating the Aβ and tau pathology in autosomal dominant Alzheimer's disease: insights from hybrid PET/MRI and network mapping.

Zhou Z, Wang Q, Liu L, Wang Q, Zhang X, Li C Alzheimers Res Ther. 2025; 17(1):45.

PMID: 39962560 PMC: 11831832. DOI: 10.1186/s13195-025-01690-1.


Functional network disruption in cognitively unimpaired autosomal dominant Alzheimer's disease: a magnetoencephalography study.

van Nifterick A, de Haan W, Stam C, Hillebrand A, Scheltens P, Van Kesteren R Brain Commun. 2024; 6(6):fcae423.

PMID: 39713236 PMC: 11660908. DOI: 10.1093/braincomms/fcae423.


Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's disease.

Cash D, Morgan K, OConnor A, Veale T, Malone I, Poole T medRxiv. 2024; .

PMID: 39606328 PMC: 11601746. DOI: 10.1101/2024.11.12.24316919.


Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer's Disease.

McDade E, Liu H, Bui Q, Hassenstab J, Gordon B, Benzinger T Res Sq. 2024; .

PMID: 39108475 PMC: 11302696. DOI: 10.21203/rs.3.rs-4202125/v1.


Is Alzheimer disease a disease?.

Korczyn A, Grinberg L Nat Rev Neurol. 2024; 20(4):245-251.

PMID: 38424454 DOI: 10.1038/s41582-024-00940-4.


References
1.
Ossenkoppele R, Rabinovici G, Smith R, Cho H, Scholl M, Strandberg O . Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2018; 320(11):1151-1162. PMC: 6233630. DOI: 10.1001/jama.2018.12917. View

2.
Gomez-Isla T, Growdon W, McNamara M, Nochlin D, Bird T, Arango J . The impact of different presenilin 1 andpresenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain: evidence for other phenotype-modifying factors. Brain. 1999; 122 ( Pt 9):1709-19. DOI: 10.1093/brain/122.9.1709. View

3.
Jack Jr C, Wiste H, Schwarz C, Lowe V, Senjem M, Vemuri P . Longitudinal tau PET in ageing and Alzheimer's disease. Brain. 2018; 141(5):1517-1528. PMC: 5917767. DOI: 10.1093/brain/awy059. View

4.
Marquie M, Normandin M, Vanderburg C, Costantino I, Bien E, Rycyna L . Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015; 78(5):787-800. PMC: 4900162. DOI: 10.1002/ana.24517. View

5.
Wang L, Benzinger T, Su Y, Christensen J, Friedrichsen K, Aldea P . Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy. JAMA Neurol. 2016; 73(9):1070-7. PMC: 5237382. DOI: 10.1001/jamaneurol.2016.2078. View